BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25826424)

  • 1. Retinoids Bias Integrin Expression and Function in Cutaneous T-Cell Lymphoma.
    Wang L; DeMarco SS; Chen J; Phillips CM; Bridges LC
    J Invest Dermatol; 2015 Aug; 135(8):2102-2108. PubMed ID: 25826424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
    Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
    Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. About the cutaneous targets of bexarotene in CTCL patients.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
    Zhang C; Duvic M
    Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis.
    Schechner JS; Edelson RL; McNiff JM; Heald PW; Pober JS
    Lab Invest; 1999 May; 79(5):601-7. PubMed ID: 10334571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
    Stadler R; Kremer A
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cutaneous T-cell lymphoma with retinoids.
    Zhang C; Duvic M
    Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
    Kempf W; Kettelhack N; Duvic M; Burg G
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells.
    Yang H; Tao Y; Zhang M; Ma P; Li L; Diao Q
    Anticancer Drugs; 2019 Jan; 30(1):56-64. PubMed ID: 30198914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
    Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
    Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
    Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
    J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL).
    Burg G; Dummer R
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S41-4. PubMed ID: 11707863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.